MedMira Inc. (MIR.V)
CAD 0.09
(-10.53%)
CAD 0.09
(-10.53%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 432.52 Thousand CAD | -54.57% |
| 2022 | 952.12 Thousand CAD | -55.6% |
| 2021 | 2.14 Million CAD | 133.33% |
| 2020 | 919.07 Thousand CAD | 74.25% |
| 2019 | 527.44 Thousand CAD | -10.43% |
| 2018 | 588.87 Thousand CAD | -21.2% |
| 2017 | 747.34 Thousand CAD | -66.89% |
| 2016 | 2.25 Million CAD | -44.31% |
| 2015 | 4.05 Million CAD | 60.29% |
| 2014 | 2.52 Million CAD | 26.32% |
| 2013 | 2 Million CAD | 106.2% |
| 2012 | 970.63 Thousand CAD | 6.68% |
| 2011 | 909.86 Thousand CAD | -15.22% |
| 2010 | 1.07 Million CAD | -5.67% |
| 2009 | 1.13 Million CAD | -25.38% |
| 2008 | 1.52 Million CAD | -10.6% |
| 2007 | 1.7 Million CAD | -18.46% |
| 2006 | 2.09 Million CAD | -21.4% |
| 2005 | 2.66 Million CAD | 9.1% |
| 2004 | 2.43 Million CAD | 107.3% |
| 2003 | 1.17 Million CAD | 926.21% |
| 2002 | 114.64 Thousand CAD | -69.32% |
| 2001 | 373.68 Thousand CAD | 376.46% |
| 2000 | 78.42 Thousand CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 148.69 Thousand CAD | 26.16% |
| 2024 Q1 | 117.86 Thousand CAD | 234.73% |
| 2024 Q3 | 81.54 Thousand CAD | -45.16% |
| 2023 FY | 432.52 Thousand CAD | -54.57% |
| 2023 Q3 | 106.01 Thousand CAD | -37.84% |
| 2023 Q4 | 35.21 Thousand CAD | -66.79% |
| 2023 Q2 | 170.53 Thousand CAD | 41.21% |
| 2023 Q1 | 120.77 Thousand CAD | -6.06% |
| 2022 Q2 | 297.48 Thousand CAD | 47.15% |
| 2022 Q1 | 202.16 Thousand CAD | 83.22% |
| 2022 FY | 952.12 Thousand CAD | -55.6% |
| 2022 Q4 | 128.55 Thousand CAD | -60.31% |
| 2022 Q3 | 323.92 Thousand CAD | 8.89% |
| 2021 Q3 | 83.86 Thousand CAD | -75.86% |
| 2021 Q1 | 1.6 Million CAD | 147.46% |
| 2021 Q2 | 347.44 Thousand CAD | -78.32% |
| 2021 Q4 | 110.33 Thousand CAD | 31.57% |
| 2021 FY | 2.14 Million CAD | 133.33% |
| 2020 Q2 | 95.01 Thousand CAD | 6.6% |
| 2020 Q4 | 647.72 Thousand CAD | 642.74% |
| 2020 Q1 | 89.13 Thousand CAD | -9.97% |
| 2020 Q3 | 87.2 Thousand CAD | -8.21% |
| 2020 FY | 919.07 Thousand CAD | 74.25% |
| 2019 Q1 | 155.06 Thousand CAD | -16.45% |
| 2019 FY | 527.44 Thousand CAD | -10.43% |
| 2019 Q2 | 129.99 Thousand CAD | -16.17% |
| 2019 Q3 | 143.38 Thousand CAD | 10.31% |
| 2019 Q4 | 99 Thousand CAD | -30.95% |
| 2018 FY | 588.87 Thousand CAD | -21.2% |
| 2018 Q1 | 143.04 Thousand CAD | -3.96% |
| 2018 Q3 | 76.36 Thousand CAD | -58.47% |
| 2018 Q2 | 183.87 Thousand CAD | 28.55% |
| 2018 Q4 | 185.59 Thousand CAD | 143.05% |
| 2017 Q4 | 148.93 Thousand CAD | -22.67% |
| 2017 Q2 | 193.57 Thousand CAD | -8.8% |
| 2017 FY | 747.34 Thousand CAD | -66.89% |
| 2017 Q1 | 212.24 Thousand CAD | 122.17% |
| 2017 Q3 | 192.59 Thousand CAD | -0.51% |
| 2016 Q1 | 1.61 Million CAD | 10.27% |
| 2016 Q4 | -957.28 Thousand CAD | -515.45% |
| 2016 Q3 | 230.41 Thousand CAD | -83.18% |
| 2016 FY | 2.25 Million CAD | -44.31% |
| 2016 Q2 | 1.37 Million CAD | -15.08% |
| 2015 Q1 | 521.17 Thousand CAD | -41.96% |
| 2015 FY | 4.05 Million CAD | 60.29% |
| 2015 Q4 | 1.46 Million CAD | 8.76% |
| 2015 Q3 | 1.34 Million CAD | 86.22% |
| 2015 Q2 | 722.5 Thousand CAD | 38.63% |
| 2014 Q1 | 472.84 Thousand CAD | -20.68% |
| 2014 FY | 2.52 Million CAD | 26.32% |
| 2014 Q2 | 518.71 Thousand CAD | 9.7% |
| 2014 Q3 | 638.63 Thousand CAD | 23.12% |
| 2014 Q4 | 897.98 Thousand CAD | 40.61% |
| 2013 Q3 | 327.25 Thousand CAD | -38.67% |
| 2013 Q1 | 544.5 Thousand CAD | 99.98% |
| 2013 FY | 2 Million CAD | 106.2% |
| 2013 Q2 | 533.59 Thousand CAD | -2.0% |
| 2013 Q4 | 596.11 Thousand CAD | 82.16% |
| 2012 Q4 | 272.27 Thousand CAD | 43.76% |
| 2012 Q3 | 189.39 Thousand CAD | -48.2% |
| 2012 FY | 970.63 Thousand CAD | 6.68% |
| 2012 Q1 | 234.77 Thousand CAD | -5.59% |
| 2012 Q2 | 365.65 Thousand CAD | 55.75% |
| 2011 Q1 | 176.86 Thousand CAD | 143.4% |
| 2011 Q2 | 188.79 Thousand CAD | 6.75% |
| 2011 Q3 | 295.53 Thousand CAD | 56.54% |
| 2011 FY | 909.86 Thousand CAD | -15.22% |
| 2011 Q4 | 248.68 Thousand CAD | -15.85% |
| 2010 Q1 | 375.8 Thousand CAD | 61.57% |
| 2010 FY | 1.07 Million CAD | -5.67% |
| 2010 Q2 | 503.77 Thousand CAD | 34.05% |
| 2010 Q3 | 601.1 Thousand CAD | 19.32% |
| 2010 Q4 | -407.51 Thousand CAD | -167.79% |
| 2009 Q4 | 232.59 Thousand CAD | -29.39% |
| 2009 Q2 | 197.27 Thousand CAD | -47.86% |
| 2009 Q1 | 378.37 Thousand CAD | 40.31% |
| 2009 FY | 1.13 Million CAD | -25.38% |
| 2009 Q3 | 329.4 Thousand CAD | 66.98% |
| 2008 FY | 1.52 Million CAD | -10.6% |
| 2008 Q3 | 400.47 Thousand CAD | -44.49% |
| 2008 Q2 | 721.43 Thousand CAD | 471.15% |
| 2008 Q1 | 126.31 Thousand CAD | 261.2% |
| 2008 Q4 | 269.66 Thousand CAD | -32.66% |
| 2007 Q4 | 34.97 Thousand CAD | -92.51% |
| 2007 Q3 | 467.17 Thousand CAD | -23.19% |
| 2007 Q2 | 608.22 Thousand CAD | 2.23% |
| 2007 Q1 | 594.95 Thousand CAD | 43.36% |
| 2007 FY | 1.7 Million CAD | -18.46% |
| 2006 Q2 | 1.13 Million CAD | 155.08% |
| 2006 Q1 | 443.63 Thousand CAD | 14.13% |
| 2006 Q3 | 101.17 Thousand CAD | -91.06% |
| 2006 Q4 | 415.01 Thousand CAD | 310.18% |
| 2006 FY | 2.09 Million CAD | -21.4% |
| 2005 Q4 | 388.71 Thousand CAD | -35.04% |
| 2005 Q3 | 598.39 Thousand CAD | -22.04% |
| 2005 Q2 | 767.55 Thousand CAD | -15.28% |
| 2005 Q1 | 906.02 Thousand CAD | 56.85% |
| 2005 FY | 2.66 Million CAD | 9.1% |
| 2004 Q2 | 508.65 Thousand CAD | -13.59% |
| 2004 Q3 | 763.93 Thousand CAD | 50.19% |
| 2004 Q1 | 588.66 Thousand CAD | -43.91% |
| 2004 FY | 2.43 Million CAD | 107.3% |
| 2004 Q4 | 577.63 Thousand CAD | -24.39% |
| 2003 Q1 | 37.12 Thousand CAD | -44.06% |
| 2003 FY | 1.17 Million CAD | 926.21% |
| 2003 Q2 | 52.66 Thousand CAD | 41.86% |
| 2003 Q3 | 37.96 Thousand CAD | -27.92% |
| 2003 Q4 | 1.04 Million CAD | 2664.48% |
| 2002 Q3 | 17.35 Thousand CAD | 31.71% |
| 2002 Q1 | 17.74 Thousand CAD | 0.0% |
| 2002 Q4 | 66.36 Thousand CAD | 282.44% |
| 2002 FY | 114.64 Thousand CAD | -69.32% |
| 2002 Q2 | 13.17 Thousand CAD | -25.75% |
| 2001 FY | 373.68 Thousand CAD | 376.46% |
| 2000 FY | 78.42 Thousand CAD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Arch Biopartners Inc. | 1.98 Million CAD | 78.195% |
| Covalon Technologies Ltd. | 26.59 Million CAD | 98.374% |
| Hemostemix Inc. | - CAD | -Infinity% |
| Universal Ibogaine Inc. | 1.07 Million CAD | 59.607% |
| Kane Biotech Inc. | 148.98 Thousand CAD | -190.327% |
| Marvel Biosciences Corp. | - CAD | -Infinity% |
| NervGen Pharma Corp. | - CAD | -Infinity% |
| XORTX Therapeutics Inc. | - CAD | -Infinity% |